Angeion's defibrillator lead to undergo US trials:
This article was originally published in Clinica
Executive Summary
Angeion plans to begin a US multicentre clinical trial of its new AngeFix 4090 lead system for defibrillators. The lead helps pace, sense and defibrillate the heart using a helix-shaped active fixation tip which can be "screwed" into the heart tissue and which also reduces the risk of the lead becoming dislodged. The Minneapolis, Minnesota-based company recently CE-marked the device which will be marketed in Europe by ELA Medical, a subsidiary of French company Synthelabo.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: